Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2017

Open Access 01-12-2017 | Research

β2 adrenergic agonist suppresses eosinophil-induced epithelial-to-mesenchymal transition of bronchial epithelial cells

Authors: Keigo Kainuma, Tetsu Kobayashi, Corina N. D’Alessandro-Gabazza, Masaaki Toda, Taro Yasuma, Kota Nishihama, Hajime Fujimoto, Yu Kuwabara, Koa Hosoki, Mizuho Nagao, Takao Fujisawa, Esteban C. Gabazza

Published in: Respiratory Research | Issue 1/2017

Login to get access

Abstract

Background

Epithelial-mesenchymal transition is currently recognized as an important mechanism for the increased number of myofibroblasts in cancer and fibrotic diseases. We have already reported that epithelial-mesenchymal transition is involved in airway remodeling induced by eosinophils. Procaterol is a selective and full β2 adrenergic agonist that is used as a rescue of asthmatic attack inhaler form and orally as a controller. In this study, we evaluated whether procaterol can suppress epithelial-mesenchymal transition of airway epithelial cells induced by eosinophils.

Methods

Epithelial-mesenchymal transition was assessed using a co-culture system of human bronchial epithelial cells and primary human eosinophils or an eosinophilic leukemia cell line.

Results

Procaterol significantly inhibited co-culture associated morphological changes of bronchial epithelial cells, decreased the expression of vimentin, and increased the expression of E-cadherin compared to control. Butoxamine, a specific β2-adrenergic antagonist, significantly blocked changes induced by procaterol. In addition, procaterol inhibited the expression of adhesion molecules induced during the interaction between eosinophils and bronchial epithelial cells, suggesting the involvement of adhesion molecules in the process of epithelial-mesenchymal transition. Forskolin, a cyclic adenosine monophosphate-promoting agent, exhibits similar inhibitory activity of procaterol.

Conclusions

Overall, these observations support the beneficial effect of procaterol on airway remodeling frequently associated with chronic obstructive pulmonary diseases.
Literature
1.
2.
3.
William W, Busse Jr aRFL. Asthma. N Engl J Med. 2001;344:351–62.
4.
5.
Eldon MA, Blake DS, Coon MJ, Nordblom GD, Sedman AJ, Colburn WA. Clinical pharmacokinetics of procaterol: dose proportionality after administration of single oral doses. Biopharm Drug Dispos. 1992;13:663–9.CrossRefPubMed
6.
Momose T, Okubo Y, Horie S, Suzuki J, Isobe M, Sekiguchi M. Effects of intracellular cyclic AMP modulators on human eosinophil survival, degranulation and CD11b expression. Int Arch Allergy Immunol. 1998;117:138–45.CrossRefPubMed
7.
Hanania NA, Moore RH. Anti-inflammatory activities of beta2-agonists. Curr Drug Targets Inflamm Allergy. 2004;3:271–7.CrossRefPubMed
8.
Butchers PR, Vardey CJ, Johnson M. Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br J Pharmacol. 1991;104:672–6.CrossRefPubMedPubMedCentral
9.
Ezeamuzie CI, al-Hage M. Differential effects of salbutamol and salmeterol on human eosinophil responses. J Pharmacol Exp Ther. 1998;284:25–31.PubMed
10.
Koyama S, Sato E, Masubuchi T, Takamizawa A, Kubo K, Nagai S, Isumi T. Procaterol inhibits IL-1beta- and TNF-alpha-mediated epithelial cell eosinophil chemotactic activity. Eur Respir J. 1999;14:767–75.CrossRefPubMed
11.
Yamaguchi T, Nagata M, Miyazawa H, Kikuchi I, Kikuchi S, Hagiwara K, Kanazawa M. Tulobuterol, aβ2-agonist, attenuates eosinophil adhesion to endothelial cells. Allergol Intern. 2005;54:283–8.CrossRef
12.
Ohbayashi H, Adachi M. Pretreatment with inhaled procaterol improves symptoms of dyspnea and quality of life in patients with severe COPD. Int J Gen Med. 2012;5:517–24.CrossRefPubMedPubMedCentral
13.
14.
Ninane V, Vandevoorde J, Cataldo D, Derom E, Liistro G, Munghen E, Peche R, Schlesser M, Verleden G, Vincken W. New developments in inhaler devices within pharmaceutical companies: a systematic review of the impact on clinical outcomes and patient preferences. Respir Med. 2015;109:1430–8.CrossRefPubMed
15.
Kannan R, Przekwas AJ, Singh N, Delvadia R, Tian G, Walenga R. Pharmachological aerosols deposition patterns from a dry powder inhaler: Euler Lagrangian prediction and validation. Med Eng Phys. 2017;42:35–47.CrossRef
16.
Kannan R, Guo P, Przekwas A. Particle transport in the human respiratory tract: formulation of a nodal inverse distance weighted Eulerian–Lagrangian transport and implementation of the Wind-Kessel algorithm for an oral delivery. Int J Numer Methods Biomed Eng. 2016;32:e02746.
17.
Kannan R, Chen ZJ, Singh N, Przekwas A, Delvadia R, Tian G, Walenga R. A quasi-3D wire approach to model pulmonary airflow in human airways. Int J Numer Methods Biomed Eng. 2016;33:e02838.
18.
Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973–81.CrossRefPubMedPubMedCentral
19.
Hosoki K, Kainuma K, Toda M, Harada E, Chelakkot-Govindalayathila AL, Roeen Z, Nagao M, D'Alessandro-Gabazza CN, Fujisawa T, Gabazza EC. Montelukast suppresses epithelial to mesenchymal transition of bronchial epithelial cells induced by eosinophils. Biochem Biophys Res Commun. 2014;449:351–6.
20.
Yasukawa A, Hosoki K, Toda M, Miyake Y, Matsushima Y, Matsumoto T, Boveda-Ruiz D, Gil-Bernabe P, Nagao M, Sugimoto M, Hiraguchi Y, Tokuda R, Naito M, Takagi T, D’Alessandro-Gabazza CN, Suga S, Kobayashi T, Fujisawa T, Taguchi O, Gabazza EC. Eosinophils promote epithelial to mesenchymal transition of bronchial epithelial cells. PLoS ONE. 2013;8:e64281.CrossRefPubMedPubMedCentral
21.
Randolph TG. Blood studies in allergy; variations in eosinophiles following test feeding of foods. J Allergy. 1947;18:199–211.CrossRefPubMed
22.
Hackett TL. Epithelial-mesenchymal transition in the pathophysiology of airway remodelling in asthma. Curr Opin Allergy Clin Immunol. 2012;12:53–9.CrossRefPubMed
23.
Hackett TL, Warner SM, Stefanowicz D, Shaheen F, Pechkovsky DV, Murray LA, Argentieri R, Kicic A, Stick SM, Bai TR, Knight DA. Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta1. Am J Respir Crit Care Med. 2009;180:122–33.CrossRefPubMed
24.
Johnson JR, Nishioka M, Chakir J, Risse PA, Almaghlouth I, Bazarbashi AN, Plante S, Martin JG, Eidelman D, Hamid Q. IL-22 contributes to TGF-beta1-mediated epithelial-mesenchymal transition in asthmatic bronchial epithelial cells. Respir Res. 2013;14:118.CrossRefPubMedPubMedCentral
25.
Pain M, Bermudez O, Lacoste P, Royer PJ, Botturi K, Tissot A, Brouard S, Eickelberg O, Magnan A. Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype. Eur Respir Rev. 2014;23:118–30.CrossRefPubMed
26.
Yang ZC, Yi MJ, Ran N, Wang C, Fu P, Feng XY, Xu L, Qu ZH. Transforming growth factor-beta1 induces bronchial epithelial cells to mesenchymal transition by activating the Snail pathway and promotes airway remodeling in asthma. Mol Med Rep. 2013;8:1663–8.PubMed
27.
Gauldie J, Bonniaud P, Sime P, Ask K, Kolb M. TGF-beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans. 2007;35:661–4.CrossRefPubMed
28.
Hansel TT, Braunstein JB, Walker C, Blaser K, Bruijnzeel PL, Virchow Jr JC, Virchow Sr C. Sputum eosinophils from asthmatics express ICAM-1 and HLA-DR. Clin Exp Immunol. 1991;86:271–7.CrossRefPubMedPubMedCentral
29.
Laudanna C, Campbell JJ, Butcher EC. Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants. J Biol Chem. 1997;272:24141–4.CrossRefPubMed
30.
Hu P, Shen M, Zhang P, Zheng C, Pang Z, Zhu L, Du J. Intratumoral neutrophil granulocytes contribute to epithelial-mesenchymal transition in lung adenocarcinoma cells. Tumour Biol. 2015;36:7789–96.CrossRefPubMed
31.
Yang Z, Xie H, He D, Li L. Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling. Oncotarget. 2016;7:44478–91.PubMedPubMedCentral
32.
Grainge CL, Lau LCK, Ward JA, Dulay V, Lahiff G, Wilson S, Holgate S, Davies DE, Howarth PH. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med. 2011;364:2006–15.
Metadata
Title
β2 adrenergic agonist suppresses eosinophil-induced epithelial-to-mesenchymal transition of bronchial epithelial cells
Authors
Keigo Kainuma
Tetsu Kobayashi
Corina N. D’Alessandro-Gabazza
Masaaki Toda
Taro Yasuma
Kota Nishihama
Hajime Fujimoto
Yu Kuwabara
Koa Hosoki
Mizuho Nagao
Takao Fujisawa
Esteban C. Gabazza
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2017
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-017-0563-4

Other articles of this Issue 1/2017

Respiratory Research 1/2017 Go to the issue

Commentary

Vitamin K deficiency: the linking pin between COPD and cardiovascular diseases?

Research

Extracellular histones are clinically relevant mediators in the pathogenesis of acute respiratory distress syndrome

Research

Whole Transcriptome Analysis of Pre-invasive and Invasive Early Squamous Lung Carcinoma in Archival Laser Microdissected Samples

Research

Evaluation of two strategies for the interpretation of tumour markers in pleural effusions

Research

Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD

Letter to the Editor

Chronic hypoxia aggravates monocrotaline-induced pulmonary arterial hypertension: a rodent relevant model to the human severe form of the disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits